Glycogen Phosphorylase Inhibitor N-(3,5-Dimethyl-Benzoyl)-N'-(β-D-Glucopyranosyl)Urea Improves Glucose Tolerance under Normoglycemic and Diabetic Conditions and Rearranges Hepatic Metabolism

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Nagy, Lilla ^a   Docsa, Tibor ^a   Szántó, Magdolna ^a,b   Brunyánszki, Attila ^a   Hegedus, Csaba ^a   Márton, Judit ^a   Kónya, Bálint ^c   Virág, László ^a,b   Somsák, László ^c   Gergely, Pál ^a,b   Bai, Péter ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOGEN PHOSPHORYLASE; GLYCOSYLTRANSFERASE INHIBITOR; KB 228; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; N (3,5 DIMETHYL BENZOYL) N' (BETA DEXTRO GLUCOPYRANOSYL)UREA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG STRUCTURE; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLYCOGEN STORAGE DISEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; GENE EXPRESSION; GLUCOSE; GLUCOSE TOLERANCE TEST; GLYCOGEN PHOSPHORYLASE; ION CHANNELS; LIVER; LIVER GLYCOGEN; MALE; MICE; MICE, OBESE; MITOCHONDRIAL PROTEINS; MULTIPROTEIN COMPLEXES; OXYGEN CONSUMPTION; TOR SERINE-THREONINE KINASES; UREA;

EID: 84880807739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069420     Document Type: Article

References (49)

1. Taniguchi CM, Emanuelli B, Kahn CR, (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96.
2. Stalmans W, Bollen M, Mvumbi L, (1987) Control of glycogen synthesis in health and disease. Diabetes Metab Rev 3: 127-161.
3. Stalmans W, Bollen M, Toth B, Gergely P, (1990) Short-term hormonal control of protein phosphatases involved in hepatic glycogen metabolism. Adv Enzyme Regul 30: 305-327.
4. Zhang T, Wang S, Lin Y, Xu W, Ye D, et al. (2012) Acetylation negatively regulates glycogen phosphorylase by recruiting protein phosphatase 1. Cell Metab 15: 75-87.
5. Aiston S, Hampson L, Gomez-Foix AM, Guinovart JJ, Agius L, (2001) Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis. J Biol Chem 276: 23858-23866.
6. Aiston S, Peak M, Agius L, (2000) Impaired glycogen synthesis in hepatocytes from Zucker fatty fa/fa rats: the role of increased phosphorylase activity. Diabetologia 43: 589-597.
7. Agius L, (2010) Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors. Mini Rev Med Chem 10: 1175-1187.
8. Baker DJ, Greenhaff PL, MacInnes A, Timmons JA, (2006) The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction. Diabetes 55: 1855-1861.
9. Docsa T, Czifrak K, Huse C, Somsak L, Gergely P, (2011) Effect of glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of streptozotocin-induced and obese diabetic rats. Mol Med Report 4: 477-481.
10. Newgard CB, Hwang PK, Fletterick RJ, (1989) The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 24: 69-99.
11. Agius L, (2007) New hepatic targets for glycaemic control in diabetes. Best Pract Res Clin Endocrinol Metab 21: 587-605.
12. Bollen M, Keppens S, Stalmans W, (1998) Specific features of glycogen metabolism in the liver. Biochem J 336 (Pt 1): 19-31.
13. Aiston S, Green A, Mukhtar M, Agius L, (2004) Glucose 6-phosphate causes translocation of phosphorylase in hepatocytes and inactivates the enzyme synergistically with glucose. Biochem J 377: 195-204.
14. Somsak L, Czifrak K, Toth M, Bokor E, Chrysina ED, et al. (2008) New inhibitors of glycogen phosphorylase as potential antidiabetic agents. Curr Med Chem 15: 2933-2983.
15. Kelsall IR, Rosenzweig D, Cohen PT, (2009) Disruption of the allosteric phosphorylase a regulation of the hepatic glycogen-targeted protein phosphatase 1 improves glucose tolerance in vivo. Cell Signal 21: 1123-1134.
16. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, et al. (1998) Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci U S A 95: 1776-1781.
17. Furukawa S, Murakami K, Nishikawa M, Nakayama O, Hino M, (2005) FR258900, a novel glycogen phosphorylase inhibitor isolated from Fungus No. 138354. II. Anti-hyperglycemic effects in diabetic animal models. J Antibiot (Tokyo) 58: 503-506.
18. Lerin C, Montell E, Nolasco T, Garcia-Rocha M, Guinovart JJ, et al. (2004) Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149. Biochem J 378: 1073-1077.
19. Varga G, Docsa T, Gergely P, Juhasz L, Somsak L (2012) Synthesis of tartaric acid analogues of FR258900 and their evaluation as glycogen phosphorylase inhibitors. Bioorg Med Chem Lett: doi: 10.1016/j.bmcl.2013.1001.1042.
20. Somsak L, (2011) Glucose derived inhibitors of glycogen phosphorylase. Compt Rend Chimie 14: 211-223.
21. Nagy V, Felfoldi N, Konya B, Praly JP, Docsa T, et al. (2012) N-(4-Substituted-benzoyl)-N'-(beta-d-glucopyranosyl)ureas as inhibitors of glycogen phosphorylase: Synthesis and evaluation by kinetic, crystallographic, and molecular modelling methods. Bioorg Med Chem 20: 1801-1816.
22. Oikonomakos NG, Somsak L, (2008) Advances in glycogen phosphorylase inhibitor design. Curr Opin Investig Drugs 9: 379-395.
23. Speziale AJ, Smith LR, Fedder J, (1965) The Reaction of Oxalyl Chloride with Amides. IV. Synthesis of Acyl Isocyanates. J Org Chem 30: 4306-4307.
24. Braña MF, López Rodriguez ML, (1981) Synthesis and reactivity of N-[α-acetoxy)-4-pyridylmethyl]-3,5-dimethylbenzamide. J Het Chem 18: 869-871.
25. Likhosherstov LM, Novikova OS, Shibaev VN, (2002) New efficient synthesis of beta-glucosylamines of mono- and disaccharides with the use of ammonium carbamate. Dokl Chem 383: 89-92.
26. Osz E, Somsak L, Szilagyi L, Kovacs L, Docsa T, et al. (1999) Efficient inhibition of muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spiro-thiohydantoin. Bioorg Med Chem Lett 9: 1385-1390.
27. Bai P, Canto C, Brunyanszki A, Huber A, Szanto M, et al. (2011) PARP-2 Regulates SIRT1 Expression and Whole-Body Energy Expenditure. Cell Metab 13: 450-460.
28. Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, et al. (2011) PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation. Cell Metab 13: 461-468.
29. Szanto M, Rutkai I, Hegedus C, Czikora A, Rozsahegyi M, et al. (2011) Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction. Cardiovasc Res 92: 430-438.
30. Brunyanszki A, Hegedus C, Szanto M, Erdelyi K, Kovacs K, et al. (2010) Genetic Ablation of PARP-1 Protects Against Oxazolone-Induced Contact Hypersensitivity by Modulating Oxidative Stress. J Invest Dermatol 130: 2629-2637.
31. Somsák L, Felföldi N, Kónya B, Hüse C, Telepó K, et al. (2008) Assessment of synthetic methods for the preparation of N-β-D-glucopyranosyl-N'-substituted ureas,-thioureas and related compounds. Carbohydr Res 343: 2083-2093.
32. Baker DJ, Timmons JA, Greenhaff PL, (2005) Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 54: 2453-2459.
33. Chrysina ED, (2010) The prototype of glycogen phosphorylase. Mini Rev Med Chem 10: 1093-1101.
34. Chrysina ED, Kosmopoulou MN, Tiraidis C, Kardakaris R, Bischler N, et al. (2005) Kinetic and crystallographic studies on 2-(beta-D-glucopyranosyl)-5-methyl-1, 3, 4-oxadiazole,-benzothiazole, and-benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site. Protein Sci 14: 873-888.
35. Baffy G, Zhang CY, Glickman JN, Lowell BB, (2002) Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology 35: 753-761.
36. Pesta D, Gnaiger E, (2012) High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol 810: 25-58.
37. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
38. Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS, et al. (2000) Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet 26: 435-439.
39. Adam-Vizi V, Chinopoulos C, (2006) Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 27: 639-645.
40. Horimoto M, Fulop P, Derdak Z, Wands JR, Baffy G, (2004) Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology 39: 386-392.
41. Fulop P, Derdak Z, Sheets A, Sabo E, Berthiaume EP, et al. (2006) Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology 44: 592-601.
42. Floettmann E, Gregory L, Teague J, Myatt J, Hammond C, et al. (2010) Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases. Toxicol Pathol 38: 393-401.
43. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
44. Laplante M, Sabatini DM, (2012) mTOR signaling in growth control and disease. Cell 149: 274-293.
45. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, et al. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859-871.
46. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
47. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, et al. (2012) Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab 15: 725-738.
48. Colombo SL, Palacios-Callender M, Frakich N, Carcamo S, Kovacs I, et al. (2011) Molecular basis for the differential use of glucose and glutamine in cell proliferation as revealed by synchronized HeLa cells. Proc Natl Acad Sci U S A 108: 21069-21074.
49. Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, et al. (2012) Glucose Utilization via Glycogen Phosphorylase Sustains Proliferation and Prevents Premature Senescence in Cancer Cells. Cell Metab 16: 751-764.